Free tool
FAERS Monitor: Sovuna
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 214581 or its brand name (Sovuna, Hydroxychloroquine Sulfate). Reports on generic versions are filed under their own applications.
Reports
40,482
Serious
35,382
87% of reports
Hospitalization
11,485
Death reported
4,537
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective18,316
- rheumatoid arthritis13,898
- pain10,999
- fatigue9,608
- drug intolerance9,402
- off label use8,673
- arthralgia8,566
- joint swelling8,555
- contraindicated product administered8,205
- alopecia7,852
- abdominal discomfort7,845
- rash7,825
- systemic lupus erythematosus7,352
- arthropathy7,333
- synovitis7,068
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 173 |
| 2005 | 231 |
| 2006 | 174 |
| 2007 | 243 |
| 2008 | 402 |
| 2009 | 368 |
| 2010 | 660 |
| 2011 | 421 |
| 2012 | 723 |
| 2013 | 208 |
| 2014 | 143 |
| 2015 | 370 |
| 2016 | 904 |
| 2017 | 1,044 |
| 2018 | 1,597 |
| 2019 | 3,281 |
| 2020 | 7,825 |
| 2021 | 5,384 |
| 2022 | 4,541 |
| 2023 | 2,948 |
| 2024 | 3,572 |
| 2025 | 3,390 |
| 2026 | 1,880 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,013,677 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| synovitisSignal | 7,068 | 334.1 | 324.8 | 1,429,101 |
| contraindicated product administeredSignal | 8,205 | 192.7 | 188.2 | 1,142,597 |
| systemic lupus erythematosusSignal | 7,352 | 135.4 | 132.3 | 779,301 |
| arthropathySignal | 7,333 | 78.8 | 77.0 | 490,198 |
| rheumatoid arthritisSignal | 13,898 | 72.3 | 71.3 | 862,621 |
| drug intoleranceSignal | 9,402 | 55.9 | 54.9 | 459,758 |
| joint swellingSignal | 8,555 | 39.6 | 38.8 | 300,402 |
| abdominal discomfortSignal | 7,845 | 25.4 | 24.9 | 176,976 |
| alopeciaSignal | 7,852 | 21.6 | 21.2 | 149,449 |
| arthralgiaSignal | 8,566 | 10.9 | 10.7 | 77,017 |
| rashSignal | 7,825 | 9.5 | 9.3 | 59,508 |
| painSignal | 10,999 | 9.5 | 9.3 | 84,115 |
| drug ineffectiveSignal | 18,316 | 7.3 | 7.2 | 104,916 |
| fatigueSignal | 9,608 | 6.5 | 6.4 | 45,657 |
| off label useSignal | 8,673 | 5.2 | 5.1 | 30,284 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.